Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease

References

• DevesaSSBrayFVizcainoAPParkinDMInternational lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates risingInt J Cancer2005117229429915900604
   PubMed Web of Science ®Google Scholar
• CamusPKudohSEbinaMInterstitial lung disease associated with drug therapyBr J Cancer200491Suppl 2S18S2315340374
   PubMed Web of Science ®Google Scholar
• RaghuGNybergFMorganGThe epidemiology of interstitial lung disease and its association with lung cancerBr J Cancer200491Suppl 2S3S1015340372
   PubMedGoogle Scholar
• MinegishiYSudohJKuribayasiHThe safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumoniasLung Cancer2011711707420493578
   PubMed Web of Science ®Google Scholar
• ShukuyaTIshiwataTHaraMCarboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung diseaseAnticancer Res201030104357436121036764
   PubMed Web of Science ®Google Scholar
• ShimizuRFujimotoDKatoRThe safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung diseaseCancer Chemother Pharmacol20147461159116625245821
   PubMed Web of Science ®Google Scholar
• EnomotoYKenmotsuHWatanabeNEfficacy and safety of combined carboplatin, paclitaxel, and bevacizumab for patients with advanced non-squamous non-small cell lung cancer with pre-existing interstitial lung disease: a retrospective multi-institutional studyAnticancer Res20153574259426326124387
   PubMed Web of Science ®Google Scholar
• SekineASatohHBabaTSafety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot studyCancer Chemother Pharmacol20167761245125227130459
   PubMed Web of Science ®Google Scholar
• OkudaKHiroseTOkiYEvaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung diseaseAnticancer Res201232125475548023225454
   PubMed Web of Science ®Google Scholar
• KinoshitaTAzumaKSasadaTChemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumoniaOncol Lett20124347748223741246
   PubMed Web of Science ®Google Scholar
• KenmotsuHNaitoTMoriKEffect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung diseaseCancer Chemother Pharmacol201575352152625563718
   PubMed Web of Science ®Google Scholar
• WatanabeNNihoSKiritaKVinorelbine and cisplatin in patients with advanced non-small cell lung cancer with interstitial pneumoniaAnticancer Res20153531697170125750330
   PubMed Web of Science ®Google Scholar
• ChoiMKHongJYChangWSafety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung diseaseCancer Chemother Pharmacol20147361217122524696125
   PubMed Web of Science ®Google Scholar
• MinegishiYTakenakaKMizutaniHExacerbation of idiopathic interstitial pneumonias associated with lung cancer therapyIntern Med200948966567219420811
   PubMed Web of Science ®Google Scholar
• GardnerERDahutWLScriptureCDRandomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxelClin Cancer Res200814134200420518594000
   PubMed Web of Science ®Google Scholar
• SocinskiMABondarenkoIKarasevaNAWeekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trialJ Clin Oncol201230172055206222547591
   PubMed Web of Science ®Google Scholar
• MacmahonHNaidichDPGooJMGuidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017Radiology2017284122824328240562
   PubMed Web of Science ®Google Scholar
• KondohYTaniguchiHKawabataYYokoiTSuzukiKTakagiKAcute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three casesChest19931036180818128404104
   PubMed Web of Science ®Google Scholar
• AzumaANukiwaTTsuboiEDouble-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosisAm J Respir Crit Care Med200517191040104715665326
   PubMed Web of Science ®Google Scholar
• YasudaYHattoriYTohnaiRThe safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung diseaseJpn J Clin Oncol2018481899329036303
   PubMed Web of Science ®Google Scholar
• FujitaTHiroishiTShikanoKThe Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial PneumoniasIntern Med201857131827183229434143
   PubMed Web of Science ®Google Scholar
• NiwaHNakaharaYYokobaMMitsufujiHSasakiJMasudaNSafety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung diseaseMol Clin Oncol20177460460828855994
   PubMedGoogle Scholar
• BrahmerJReckampKLBaasPNivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• ReckMRodríguez-AbreuDRobinsonAGPembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung CancerN Engl J Med2016375191823183327718847
   PubMed Web of Science ®Google Scholar
• KanaiOKimYHDemuraYEfficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung diseaseThorac Cancer20189784785529782069
   PubMed Web of Science ®Google Scholar
• KenmotsuHNaitoTKimuraMThe risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancerJ Thorac Oncol2011671242124621623239
   PubMed Web of Science ®Google Scholar
• ImaiHKairaKMinatoKClinical significance of post-progression survival in lung cancerThorac Cancer20178537938628627767
   PubMed Web of Science ®Google Scholar
• ImaiHMoriKWataseNClinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancerThorac Cancer20167665566227755823
   PubMed Web of Science ®Google Scholar
• American Thoracic Society, European Respiratory SocietyAmerican Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001Am J Respir Crit Care Med2002165227730411790668
   PubMedGoogle Scholar
• FlahertyKRKingTERaghuGIdiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?Am J Respir Crit Care Med2004170890491015256390
   PubMed Web of Science ®Google Scholar
• HunninghakeGWZimmermanMBSchwartzDAUtility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosisAm J Respir Crit Care Med2001164219319611463586
   PubMed Web of Science ®Google Scholar
• JohkohTMüllerNLCartierYIdiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patientsRadiology1999211255556010228542
   PubMed Web of Science ®Google Scholar
• RaghuGMagetoYNLockhartDSchmidtRAWoodDEGodwinJDThe accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective studyChest199911651168117410559072
   PubMed Web of Science ®Google Scholar
• SwensenSJAughenbaughGLMyersJLDiffuse lung disease: diagnostic accuracy of CT in patients undergoing surgical biopsy of the lungRadiology199720512292349314990
   PubMed Web of Science ®Google Scholar